- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00924508
Hydrogel Patch for the Treatment of Eczema
December 30, 2013 updated by: University of California, San Francisco
A Study to Compare the Efficacy of Triamcinolone 0.1% Cream Occluded With Hydrogel Patch to Triamcinolone 0.1% Cream Without Occlusion in the Treatment of Eczema
The primary objective of this clinical study is to determine whether occlusion of triamcinolone 0.1% cream (TAC) with hydrogel patch improves its efficacy in treating eczema.
A secondary objective is to determine whether eczema improves under occlusion with hydrogel patch alone, without TAC.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This will be a 6-week, open label, bilaterally-controlled single center study involving 30 subjects age 13 and older with eczema.
The primary objective of this clinical study is to determine whether occlusion of triamcinolone 0.1% cream (TAC) used to treat eczema with hydrogel patch improves its efficacy.
A secondary objective is to determine whether eczema improves under occlusion with hydrogel patch alone.
All subjects will have 3 target lesions of similar severity followed throughout the study.
Patients will apply hydrogel patch alone to the first lesion, TAC 0.1% cream to the second lesion, and TAC 0.1% cream occluded by hydrogel patch to the third lesion.
All treatments are twice a day for a maximum of 4 weeks or until lesions are cleared.
The modified Eczema Area and Severity Index (EASI) score will be used to evaluate each lesion.
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94118
- UCSF Psoriasis Skin and Treatment Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject has signed the informed consent form and Health Insurance Portability and Accountability Act (HIPAA) authorization form;
- Male or female subject at least 12 years of age; subjects under 18 years of age will need parental or official guardian consent.
- A diagnosis of eczema with at least three lesions no larger than 7 by 7 cm on either the trunk, arms, or legs that would serve as target lesions. The lesions must be wide enough apart so that there is no overlap of hydrogel patches. All three lesions must have at least 5 out of 12 points on the modified EASI scale. Each of the three lesions must have no greater than 1 point difference from each other on the modified EASI score. (If the subject can identify specific eczema lesions that are more pruritic, recalcitrant and/or tend to initiate the itch-scratch cycle, then those lesions will be preferentially selected as the target lesions.)
- Any additional diagnoses must, in the investigator's opinion, not preclude the subject from safely participating in this study or interfere with the evaluation of the subject's eczema;
- Subject is able to completely discontinue the use of any medication or therapy (other than study medications) for relief of eczema in the target areas to be treated;
- Subject is able to completely discontinue the use of any systemic medication or therapy (e.g. oral medications, phototherapy, herbal remedies, or acupuncture) for relief of eczema;
- Subject must be reliable and mentally competent to complete study measurements;
- Subject is able to understand and agrees to comply with study requirements, attend study visits, and comply with the restrictions during the study.
Exclusion Criteria:
- Subjects with exclusively hand, face, foot, and/or groin dermatitis
- Known hypersensitivity to any component of the test medications;
- Pigmentation, extensive scarring, or pigmented lesions in affected areas that would interfere with evaluation of efficacy parameters;
- Clinically infected eczema at baseline.
- Any evidence of atrophy in the areas selected for treatment with topical corticosteroid;
- Subjects requiring any other medication (topical or systemic) that may affect the course of the disease during the study period (e.g. oral corticosteroids, immunosuppressants, antibiotics, sedating antihistamines). Inhaled steroids will be permitted.
- Topical therapies (other than non-prescription emollients) on potential target lesions within one week of starting study treatment;
- Systemic therapy, phototherapy, or a systemic investigational therapy for eczema within 30 days prior to study entry;
- Subject is considered unreliable as to medication compliance or adherence to scheduled appointments as determined by the investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patch + cream, patch alone, cream alone
This is a single arm study.
Each subject will have 3 target lesions; one treated with TAC 0.1% cream and hydrogel patch (occlusion), the second treated with cream alone, and the third treated with occlusion alone.
|
occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
Other Names:
Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent.
Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Disease Severity: Percent Change in Mean EASI Score
Time Frame: Baseline, 6 weeks
|
Percent change in mean EASI score week 0 to week 6: Each lesion was scored using a 12-point modified Eczema Area and Severity Index (EASI) at baseline and 2 weeks after the 4-week treatment period (week6).
An experienced evaluator assessed each lesion on the severity of 4 domains, with higher scores indicating more severity: 1) intensity of redness (erythema), 2) thickness (induration, papulation, oedema), 3) scratching (excoriation) and 4) lichenification (lined skin) as as none (0), mild (1), moderate (2) and severe (3).
Pictorial and descriptive instructions guided the evaluator in scoring the lesions based on visual appearance.
|
Baseline, 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Adverse Events Associated With Treatment
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2008
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
July 1, 2012
Study Registration Dates
First Submitted
June 17, 2009
First Submitted That Met QC Criteria
June 18, 2009
First Posted (Estimate)
June 19, 2009
Study Record Updates
Last Update Posted (Estimate)
January 31, 2014
Last Update Submitted That Met QC Criteria
December 30, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Dermatitis
- Skin Diseases, Eczematous
- Eczema
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
Other Study ID Numbers
- Hydrogel for Eczema
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eczema
-
Technical University of MunichCelgene CorporationCompletedEczema | Nummular Eczema | Dermatitis Eczema | Nummular DermatitisGermany
-
Odense University HospitalCompletedVesicular Palmoplantar Eczema | PompholyxDenmark
-
Gary GoldenbergCompletedHand Eczema | Foot EczemaUnited States
-
University Hospitals Coventry and Warwickshire...University of WarwickNot yet recruitingCancer | Skin Cancer | Dry Skin; Eczema | Medical Device Site EczemaUnited Kingdom
-
Zealand University HospitalUniversity of Copenhagen; Danish Working Environment FundCompleted
-
SalvatCompleted
-
University Hospital Bispebjerg and FrederiksbergStatens Serum InstitutRecruiting
-
BayerCompleted
-
Cosmetique Active InternationalCompleted
Clinical Trials on hydrogel patch
-
Chinese PLA General HospitalRecruitingPostoperative DeliriumChina
-
Teikoku Seiyaku Co., Ltd.ClinSearch; Clinigen, Inc.; CRM Biometrics GmbHCompletedSoft Tissue Injuries | Sprains | Contusions | Strains | BruisesGermany
-
Teikoku Seiyaku Co., Ltd.TerminatedAnkle SprainUnited States
-
Kyunghee University Medical CenterUnknown
-
Sun Yat-sen UniversityCompletedAnkylosing SpondylitisChina
-
SocraTec R&D GmbHSocraMetrics GmbH; Teikoku Seiyaku Co., Ltd.CompletedComparative BioavailabilityGermany
-
University of WashingtonNational Cancer Institute (NCI)CompletedBladder CarcinomaUnited States
-
Halscion, Inc.Completed
-
University of VirginiaMicrovention-Terumo, Inc.Terminated
-
Chulalongkorn UniversityNot yet recruitingWound | Skin Graft Scar | Donor Site Complication | Scar Conditions and Fibrosis of SkinThailand